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The incidence of cutaneous melanoma (CM) has increased in the past few dec-
ades. The biology of melanoma is characterized by a complex interaction
between genetic, environmental and phenotypic factors. A greater understand-
ing of the molecular mechanisms that promote melanoma cell growth and dis-
semination is crucial to improve diagnosis, prognostication, and treatment of
CM. Both small and long non-coding RNAs (lncRNAs) have been identified
to play a role in melanoma biology; microRNA and lncRNA expression is
altered in transformed melanocytes and this in turn has functional effects on
cell proliferation, apoptosis, invasion, metastasis, and immune response.
Moreover, specific dysregulated ncRNAs were shown to have a diagnostic or
prognostic role in melanoma and to drive the establishment of drug resistance.
Here, we review the current literature on small and lncRNAs with a role in
melanoma, with the aim of putting into some order this complex jigsaw puzzle.
1. Clinical aspects of cutaneous
melanoma
The incidence of cutaneous melanoma (CM) has
increased in the past few decades. The worldwide high-
est incidence is reported in Australia (36–50/100 000
people). In Europe, the lowest incidence occurs in the
Southern and the highest in the Northern countries
(10–20 cases/100 000) (Arnold et al., 2014). CM
accounts for 3–5% of all cutaneous cancers. Most
cases of CM are diagnosed at an early stage and are
curable with surgical excision. On the other hand, the
diagnosis of an advanced CM represents a therapeutic
challenge, due to the low sensitivity to chemotherapy
demonstrated by this tumor (Viros et al., 2008).
The 5-year survival for CM is 91% overall. Patients
with early-stage disease have a 5-year survival rate of
about 98%, but this rate drastically decreases when
regional or distant metastases are present, ranging
from 63% to 16%, respectively (Box and Terzian,
2008; Haferkamp et al., 2009; McKenzie et al., 2010).
The pathogenesis of CM is complex and includes
genetic, environmental (UV radiation exposure) and
phenotypic factors (fair phototypes, multiple nevi, pos-
itive family history for melanoma). Studies on germ-
line mutations focusing on the cyclin-dependent kinase
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inhibitor 2A (CDKN2A), have shown mutations in
5–15% of familial cases affected by CM. Other suscep-
tibility genes include MITF, CDK4, POT1, ACD,
TERF2IP, BAP1 and TERT promoter (van Dijk et al.,
2005; Garrido and Bastian, 2010; Hacker et al., 2010;
Jovanovic et al., 2010; Soura et al., 2016). Neverthe-
less, the majority of melanomas are non-familial and
sporadic. For these patients, the recognition of the
orchestra of genetic and epigenetic regulatory mecha-
nisms involved in the development and progression of
melanoma has permitted in the last two decades an
improvement in the clinical management of patients
affected by metastatic disease. Indeed, the knowledge
of genetic alterations in primary and metastatic tumors
has offered clinically actionable targets.
Cutaneous melanoma has one of the highest geno-
mic mutational burdens (number of mutations per
megabase) among human cancers (Chalmers et al.,
2017). This is specifically true for the cutaneous sub-
type and not acral or mucosal subtypes, because of the
effect of UV exposure. Recently, the landscape of
genomic alterations characterizing human cancers has
been made available through The Cancer Genome
Atlas (TCGA) project. In the context of this project,
333 samples of primary and metastatic cutaneous mel-
anoma (SKCM) were analyzed by Whole Exome
Sequencing and classified into four main genomic sub-
types: mutant BRAF, mutant NRAS, mutant neurofi-
bromatosis type 1 (NF1) and triple-wild-type (Cancer
Genome Atlas, 2015). In 2017, a more detailed analy-
sis of whole genome alterations of 183 melanoma sam-
ples reported BRAF, CDNK2A, NRAS and TP53 as
the most frequently mutated genes in CM (Hayward
et al., 2017). When copy number variations were
included in this classification, CM was characterized
by dysregulation in the following signaling pathways:
MAPK in 92% of the samples, PI3K in 56%, RTKs
in 48%, Histone modification in 48%, Cell cycle in
40%, SWI/SNF in 38%, TP53 in 37% and WNT in
29%. In Fig. 1, we present a picture of the most sig-
nificantly mutated genes in melanoma, obtained using
TCGA SKCM samples.
MAPK pathway members include RAS, RAF,
MEK and ERK. The main function of the MAPK
pathway is to transfer extracellular signals from the
cell membrane to the nucleus, using protein phospho-
rylation, finally promoting cell proliferation (van Dijk
et al., 2005; Jovanovic et al., 2010; Mishra et al., 2010;
Takata and Saida, 2006). Understanding of this path-
way is hindered by the presence of multiple isoforms
of the RAS, RAF, MEK and ERK proteins, which
have different functions and whose specific regulatory
aspects are yet not fully understood.
The RAF family consists of A-RAF, BRAF and
C-RAF, which are protein kinases frequently mutated
in cancer. BRAF gene mutations are found in 52% of
melanomas (Cancer Genome Atlas Network, 2015),
and 90% of those mutations are a single nucleotide
alteration (nucleotide 1799 T>A), resulting in substitu-
tion of glutamic acid for valine (BRAFV600E)
(Ascierto et al., 2012). This mutation causes the consti-
tutive activation of the kinase and also insensitivity to
negative feedback mechanisms, finally promoting
angiogenesis (via HIFa and VEGF activation), apop-
tosis evasion, invasion and metastasis (Maurer et al.,
2011). BRAFV600E also regulates interleukin (IL)-8,
which promotes the adhesion of melanocytes to the
vasculature, thereby helping to promote metastases
(Singh et al., 1994). In addition, BRAF mutations have
been also detected in typical and atypical melanocytic
nevi. In nevi, BRAF mutations initially trigger growth
in lesions that will eventually stop proliferating and
remain benign (Michaloglou et al., 2005). This onco-
gene-induced senescence is theorized to occur in the
82% of melanocytic nevi with BRAF mutations (Waja-
peyee et al., 2008). A second mutation causing the loss
of a tumor-suppressor gene or causing a second muta-
tion could cause a transition from ‘benign’ BRAF-
mutated nevi to malignant melanoma (Arkenau et al.,
2011; Jovanovic et al., 2010; McKenzie et al., 2010;
Michaloglou et al., 2005).
The RAS family of proteins contains N-RAS, K-
RAS and H-RAS. NRAS mutations have been found
in 28% of melanomas (Cancer Genome Atlas Net-
work, 2015), mostly occurring on chronically sun-
exposed skin (van Dijk et al., 2005; Dong et al., 2003;
Jovanovic et al., 2010). Most mutations in NRAS
occur at codon 61 and make the protein constitutively
active. Mouse models have revealed a requirement for
concurrent loss of CDKN2A/p16, a tumor-suppressor
gene, to develop melanoma (Dong et al., 2003). NRAS
mutations are mutually exclusive with BRAF muta-
tions with very rare exceptions (van Dijk et al., 2005).
KRAS and HRAS mutations have been found respec-
tively in 2% and 1% of CM.
MEK1 and 2 are protein kinases that are down-
stream of BRAF. MEK is active in 30% of all cancers.
Inhibitors for the protein have been developed as ther-
apeutic targets for BRAF-mutated melanomas
(McKenzie et al., 2010).
ERK1 and 2 are the only proteins downstream of
MEK. They phosphorylate microphthalmia-associated
transcriptional factor (MITF), which regulates melano-
cyte differentiation. ERK activation has been reported
in melanoma, and activated ERKs are present at lower
levels in the melanocytes of normal-appearing skin.
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In the last few years, the detection of somatic muta-
tions, the development of target therapies, and the
introduction of immune checkpoint inhibitors have led
to important therapeutic advances for melanoma
patients (Kirchberger et al., 2018).
The first targeted therapy to be introduced was
monotherapy with BRAF inhibitors such as vemu-
rafenib or dabrafenib for the treatment of advanced
BRAF-mutant melanoma (Martin-Liberal and Larkin,
2015). These drugs improve the outcome of patients with
advanced BRAF V600-mutant melanoma, with a high
rate of tumor response and improvement in progression-
free survival and overall survival compared with stan-
dard cytotoxic chemotherapy. Nonetheless, the acquired
resistance to BRAF inhibitor monotherapy represents
the most common cause of treatment failure, due to the
reactivation of MAPK pathway through MEK.
MEK inhibitors were than introduced in combina-
tion with BRAF-targeted therapy, demonstrating bene-
fits in randomized clinical trials, not solely attenuating
the development of resistance but also improving pro-
gression-free survival and overall survival with respect
to BRAF inhibitors alone (Long et al., 2014; Mai
et al., 2015; Spagnolo et al., 2014).
Recently, immunotherapy with checkpoint inhibitors
targeting cytotoxic T lymphocyte-associated antigen 4,
CTLA-4 (ipilimumab) and programmed death 1, PD-1
(pembrolizumab and nivolumab) have also been demon-
strated to provide durable effects in metastatic mela-
noma, which improved when combined together (Larkin
et al., 2015; Weber et al., 2017; Wolchok et al., 2017).
Future investigations are needed to better compre-
hend the mechanism of primary or secondary resis-
tance to immune checkpoint inhibitors and targeted
therapies. This could be avoided by targeting other
players in the tumor microenvironment or acting on
other dysregulated molecules inside the tumor cell,
including non-coding RNAs (ncRNAs).
2. Non-coding RNA dysregulation in
cancer
In the past two decades, dysregulated expression of
small ncRNAs, including microRNAs (miRNAs), and
lncRNAs has been reported in many, if not all, tumor
types. The relevance of ncRNA in cancer development
is becoming clearer with every passing day: ncRNAs
constitute an additional layer of complexity in the cel-
lular regulatory machinery and their alteration is a
well-established driver of cancer in addition to genetic,
epigenetic and protein-coding gene expression dysregu-
lation. Much effort has focused on identifying which
ncRNA molecules are altered in each cancer type,
including melanoma.
The ENCODE project revealed that 80% of the
human genome is biochemically functional (Djebali
et al., 2012). Non-coding transcripts constitute the
majority of RNA molecules generated from the active
genome, making up 97% of the transcriptome (Moraes
and Goes, 2016). The exact type, role and function of
all non-coding transcripts is still under evaluation,
although some ncRNA classes have been better studied
than others. Among the small ncRNAs (size < 200 nt),
the most studied are undoubtedly miRNAs. It is well
known that human miRNAs can actively regulate pro-
tein-coding gene transcription by binding to the 30-
UTR of target mRNAs, therefore inducing their degra-
dation or blocking their transcription. We also know
that lncRNAs fulfil a series of regulatory functions in
the cell, including organization of nuclear architecture,
recruitment of chromatin-modifying proteins, modula-
tion of protein–DNA binding, and regulation of
mRNA stability and translation (Paralkar and Weiss,
2013; Rutenberg-Schoenberg et al., 2016; Tan and Mar-
ques, 2014; Tan et al., 2014; Vance and Ponting, 2014).
In 2012, thousands of circular RNAs (circRNAs)
were discovered (Salzman et al., 2012). circular RNAs
are particularly stable and resistant to RNA degrada-
tion and act as very powerful ‘miRNA sponges’.
According to the competing endogenous RNAs
hypothesis, any RNA molecule can potentially regulate
the level of multiple transcripts by subtracting miR-
NAs from other RNAs that share the same miRNA
responsive element (Salmena et al., 2011). Starting
from this scenario, we can only begin to imagine how
complex the interactions between coding and non-cod-
ing RNAs could be. Indeed, dysregulated lncRNAs
could indirectly modulate mRNA levels by competing
for miRNA targeting the same gene, thus altering pro-
tein localization and function.
In this review, we cover the state-of-the-art research
on ncRNAs in melanoma by presenting and discussing
Fig. 1. Plot of significantly mutated genes from the MUTSIG2.0 computational analysis of whole-exome sequencing data from a SKCM TCGA
cohort obtained from the Firebrowse website (Cancer Genome Atlas Research, 2011). Genes are ordered by level of significance (q value at
right). At left is the prevalence of each mutation in the sample set. The top graph shows the number of mutations per sample, subclassified
as synonymous (Syn) and non-synonymous (Non syn). The bottom plots show the distribution of allelic fraction of mutations for each
sample and the frequency of the different types of genetic alterations.
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all the most relevant studies published from 2008 to
2018.
2.1. MicroRNA dysregulation in melanoma
Since the discovery of miRNAs, several studies have
reported miRNA dysregulation in human cancers,
including melanoma (Hanniford et al., 2015; Howell
et al., 2010; Kozubek et al., 2013; Mueller et al., 2009;
Philippidou et al., 2010; Stark et al., 2010). Depending
on the targets they regulate and the tissue where they
are expressed, miRNAs can have oncogenic or tumor-
suppressive roles. Oncogenic miRNAs, known as
oncomiRs, target and downregulate tumor-suppressor
genes. On the other hand, some miRNAs can have a
protective role downregulating genes associated with
growth and metastasis. An imbalance of these two
types of miRNA, specifically upregulation of onco-
miRs and downregulation of tumor-suppressor miR-
NAs, affects tumor development and progression
(Negrini et al., 2007; Zhang et al., 2007).
For a better understanding of the functional role of
miRNAs in melanoma, we organized the main experi-
mental discoveries according to the cancer hallmark
that is influenced by the miRNA. These results are
summarized in Table 1.
As a technical note, we would like to emphasize that
given the changes in mature miRNA naming that have
occurred over the years (see miRBase database http://
www.mirbase.org/help/nomenclature.shtml, Ambros
et al., 2003), it was sometimes difficult to determine the
identity of mature miRNAs in certain research articles,
especially after the broader introduction of the 3p
and 5p suffixes convention for mature miRNA nam-
ing as a substitute for the star (*) symbol for the less
predominant form. Here, we decided to use theoriginal
name of the mature miRNA, as used in the reference
paper, but we provided an MIRBASE v.22 update name
in the Tables. An MIRBASE TRACKER tool was used for
miRNA name conversion (Van Peer et al., 2014).
2.1.1. MicroRNAs involved in melanoma biology
Microphthalmia-associated transcription factor
(MITF) is the leading regulator of melanocyte devel-
opment, survival and function (Levy et al., 2006). In
melanoma, it was observed that MITF is both regu-
lated by and regulates miRNAs.
The most cancer-specific dysregulated miRNA in
melanoma is miR-211-5p, which is indeed transcribed
by MITF together with its host gene, melastatin
(TRPM1), in human melanocytes. Several studies
demonstrated that miR-211 is one of the most
differentially expressed miRNAs between melanoma
cell lines and normal human melanocytes (Levy et al.,
2010; Mazar et al., 2010; Xu et al., 2012). In primary
melanoma, miR-211 is downregulated, and it is down-
regulated even further in malignant melanoma.
TRPM1/miR-211 levels are frequently downregulated
or lost during the transition from nevi to primary mela-
noma, and high TRPM1 levels correlate with longer
disease-free survival in primary melanoma patients
(Hammock et al., 2006). MicroRNA is also involved in
the regulation of cellular adhesion through the upregu-
lation of NUAK1 (Bell et al., 2014). Overexpression of
miR-211 results in an increase in pigmentation via an
increase in the total number of melanosomes and
potentiates the pigmentation induced by vemurafenib
by increasing the number of heavily pigmented stage IV
melanosomes. The role of miR-211 in melanotic mela-
noma cells is to contribute to a ‘normalization pro-
gram’ activated by the inhibition of the ERK pathway:
the resulting de-repression of MITF promotes a switch
from glycolysis to oxidative phosphorylation involving
PGC1alpha and mitochondrial biogenesis. This induces
a more differentiated phenotype mediated by TRPM1/
miR-211 and the melanin biosynthetic pathway
(Vitiello et al., 2017).
It was observed that MITF is also regulated by
miRNAs such as miR-182 and miR-137 which directly
target MITF, leading to extracellular matrix degrada-
tion and, consequently, tumor cell migration and inva-
sion (Bemis et al., 2008; Segura et al., 2009).
2.1.2. MicroRNAs involved in cell proliferation
Melanoma cell proliferation can be influenced by miR-
NAs; in fact the dysregulation of some miRNAs can
sustain and induce proliferative signals or repress
growth-suppressive pathways, thereby promoting mela-
noma carcinogenesis. Moreover, miRNAs can affect
proliferation by regulating proteins involved in the cel-
lular cycle.
One of the miRNAs involved in melanoma cell pro-
liferation is miR-21-5p (formerly miR-21). The miR-
21-5p is upregulated in melanoma cell lines relative to
melanocytes (Satzger et al., 2012), and in primary mel-
anoma compared with benign nevi (Grignol et al.,
2011). Upregulation of this miRNA is present in pri-
mary lesions with histological atypia and mitotic activ-
ity (Grignol et al., 2011). In addition, miR-21-5p is
upregulated in metastatic melanoma compared with
primary melanoma (Jiang et al., 2012). Increased
expression of miR-21-5p affects proliferation, migra-
tion and apoptosis. Knockdown of miR-21-5p in mela-
noma cell lines reduces cell proliferation and
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Table 1. MicroRNAs (miRNAs) dysregulated in human cutaneous melanoma and classified according to their main function in tumor cells.
miRNAa
Expression in melanoma vs.
normal melanocytes Target gene(s)
Reference(s) on target
gene regulation
Melanoma biology
211-5p Downregulated MITF/TRPM1 Hammock et al. (2006)
Downregulated NUAK1 Bell et al. (2014)
Downregulated ERK Vitiello et al. (2017)
182-5p, 137 Upregulated, not-specified MITF Bemis et al. (2008), Segura et al. (2009)
Cell proliferation and cycle
21-5p Upregulated PDCD4, PTEN, BTG2 Yang et al. (2011)
155-5p Upregulated SKI Levati et al. (2011)
135a-5p Upregulated FOXO1 Ren et al. (2015)
145-5p Downregulated c-MYC Noguchi et al. (2012a)
125b-5p Downregulated Nyholm et al. (2014)
Let-7 family Downregulated Rb Schultz et al. (2008)
206 Downregulated CDK4, CCND1, Cyclin C Georgantas et al. (2014)
193b-3p Downregulated CCND1 Chen et al. (2010)
137 Downregulated c-Met, YB1, MITF, EZH2 Luo et al. (2013b)
365a-3p Downregulated CCND1 Zhu et al. (2018)
101-3p Downregulated MITF, EZH2 Luo et al. (2013a)
205-5p Downregulated ZEB2 Liu et al. (2012b)
Downregulated E2F1, E2F5 Dar et al. (2011)
203a-3p Downregulated BMI1 Chang et al. (2015)
Downregulated E2F3a, E2F3b Noguchi et al. (2012b)
126-3p, 126-5p Downregulated ADAM9, MMP7 Felli et al. (2013)
194-5p Downregulated PI3K/AKT/FoxO3a Bai et al. (2017)
Downregulated GEF-H1 Guo et al. (2016b)
485-5p Downregulated FZD7 Wu et al. (2017)
136-5p Downregulated PMEL Wang et al. (2017b)
31-5p Downregulated PI3K/AKT Zheng et al. (2018)
Apoptosis
18b-5p Downregulated MDM2 Dar et al. (2013)
638 Upregulated TP53INP2 Bhattacharya et al. (2015)
21-5p Upregulated PDCD4, PTEN, BTG2 Yang et al. (2011)
Upregulated PTEN, BCL-2, pAKT Syed et al. (2013)
4286 Upregulated FPGS, RRN3, APLN, GPR 55,
HMGA1
Komina et al. (2016)
15b-5p Upregulated Caspase 3 and 7 and Annexin V Satzger et al. (2010)
125b-5p Downregulated Glud et al. (2010), Holst et al. (2011),
Nyholm et al. (2014)
205-5p Downregulated E2F1, RB Dar et al. (2011)
26a-5p Downregulated SODD Reuland et al. (2013)
Invasion and metastasis
150-5p Upregulated MYB, EGR2, NOTCH3, cytokine
signaling cascade
Fleming et al. (2015), Howard et al.
(2013), Kunz (2013)
211-5p Downregulated TGFB Levy et al. (2010)
Downregulated BRN2 Boyle et al. (2011)
Downregulated KCNMA1 Mazar et al. (2010)
101-5p Downregulated MITF, EXH2 Luo et al. (2013a)
200c-3p Upregulated MARCKS Elson-Schwab et al. (2010)
203a-3p Downregulation BMI1 Chang et al. (2015)
9-5p Downregulation SNAI1, NF-jB1, E-cadherin Liu et al. (2012a)
182-5p Upregulated FOXO3, MITF Segura et al. (2009)
21-5p Upregulated TIMP3 Martin del Campo et al. (2015), Yang
et al. (2011)
Let-7a-5p Downregulated NRAS, integrin b3 Muller and Bosserhoff (2008)
34a-5p Downregulated P53 Yamazaki et al. (2012)
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migration, and promotes apoptosis by increasing the
expression of programmed cell death 4 (PDCD4),
phosphate and tensin homolog (PTEN) and BTG fam-
ily member 2 (BTG2) (Yang et al., 2011).
Upregulation of miR-155 occurs in primary mela-
noma compared with benign nevi (Grignol et al.,
2011), in melanoma with positive sentinel lymph node
biopsy compared with negative sentinel biopsy (Grig-
nol et al., 2011), and in primary melanoma and meta-
static melanoma compared with benign nevi
(Philippidou et al., 2010; Segura et al., 2010). Contrary
to what might be expected, in vitro experiments
demonstrated that overexpression of miR-155 results
in inhibition of cellular proliferation and promotion of
apoptosis (Levati et al., 2009) through targeting of v-
ski avian sarcoma viral oncogene homolog (SKI;
Levati et al., 2011).
A study has found that miR-135a, which promotes
cell proliferation and the cell cycle, is upregulated in
malignant melanoma tissue and cell lines. It was
observed that ectopic expression of miR-135a inhibits
Forkhead box protein O1 (FOXO1) protein, leading
to an upregulation of Cyclin D1 (CCND1) and down-
regulation of P21Cip1 and P27Kip1 through the AKT
pathway (Ren et al., 2015).
Conversely, there are miRNAs that act as tumor sup-
pressors and whose downregulation in cancer cells
increases the proliferation rate: miR-145, miR-125b and
miR-206. Of these, miR-145 is dysregulated in many
solid tumors and is also downregulated in melanoma. In
melanoma cell lines, it was observed that ectopic expres-
sion of miR-145 inhibits cell growth by targeting c-
MYC (Noguchi et al., 2012a). In melanoma, miR-125b
is downregulated compared with normal skin (Holst
et al., 2011). This downregulation was also demon-
strated in melanoma cell lines relative to human epider-
mal melanocytes (Kappelmann et al., 2013; Zhang
et al., 2014), in atypical nevi in comparison with com-
mon nevi (Holst et al., 2011) and in melanoma with
lymph node involvement (N+) compared with mela-
noma without lymph node involvement (N0) (Glud
et al., 2010). Experimentally, the overexpression of
miR-125b in melanoma cell line (Mel-Juso) resulted in
decreased proliferation and cell cycle arrest (Nyholm
et al., 2014). A significant downregulation of miR-206
was found in melanoma cells compared with normal
melanocytes. This miRNA targets cyclin-dependent
kinase 4 (CDK4), cyclin D1 (CCND1) and cyclin C,
and transfection of miR-206 induces G1 arrest in multi-
ple melanoma cell lines (Georgantas et al., 2014).
An important miRNA family that controls cell pro-
liferation is the let-7 family. The expression of let-7a,
let-7b and let-7d is significantly decreased in melanocy-
tic nevi compared with primary melanoma (Schultz
Table 1. (Continued).
miRNAa
Expression in melanoma vs.
normal melanocytes Target gene(s)
Reference(s) on target
gene regulation
Downregulated FLOT2 Liu et al. (2015b)
365a-3p Downregulated NPL1 Bai et al. (2015)
7-5p Downregulated IRS-2/Akt Giles et al. (2013)
125b-5p Downregulated c-Jun Kappelmann et al. (2013)
Downregulated MLK3, MMK7 Zhang et al. (2014)
542-3p Downregulated PIM1 Rang et al. (2016)
124-3p Downregulated RLIP76 Zhang et al. (2016)
625-5p Downregulated SOX2 Fang et al. (2017)
153-3p Downregulated SNAI1 Zeng et al. (2017)
137 Downregulated MITF, c-Met, YB-1, EZH2 Luo et al. (2013b)
339-3p Downregulated MCL1 Weber et al. (2016)
214-3p Upregulated ITGA5, ALCAM Orso et al. (2016)
148b-3p Downregulated
Immune response
210-3p Downregulated PTPN1, HOXA1, TP53I11 Noman et al. (2012)
30b-5p/30d-5p Upregulated GALNT7 Gaziel-Sovran et al. (2011)
17-5p Downregulated STAT3 Li et al. (2014a)
34a/c-5p Downregulated ULBP2 Heinemann et al. (2012)
21-5p, 29a-3p, 142-
3p, 223-3p
Upregulated CSF1-ETS2 Mathsyaraja et al. (2015)
34a/c-5p, 499a/c Downregulated ULBP2 Heinemann et al. (2012)
28-5p Downregulated TIM3, BTLA, PD-1 Li et al. (2016)
a MicroRNA names are updated to MIRBASE release 22 (March 2018).
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et al., 2008). The overexpression of miR-let-7b in mel-
anoma cell lines decreased expression of cyclins D1,
D3 and A, which are important for blocking the
tumor-suppressor retinoblastoma protein (Rb) and
promoting proliferation in melanoma (Schultz et al.,
2008).
The expression of miR-193b was found to be 3.4-
fold lower in metastatic melanoma than in benign
nevi. It was also observed that overexpression of miR-
193b in melanoma cell lines inhibits proliferation. In
addition, it was demonstrated that miR-193b directly
targets CCND1 (Chen et al., 2010). It was suggested
that dysregulation of this miRNA may contribute to
melanoma progression. Similarly, miR-137 is involved
in the regulation of cell proliferation and is downregu-
lated in melanoma cell lines from a stage IV patient
compared with normal human melanocytes. It was
demonstrated that miR-137 inhibits proliferation medi-
ated by tyrosine-protein kinase Met (c-Met), Y box
binding protein 1 (YB1), MITF, and enhancer of zeste
homolog 2 (EZH2) (Luo et al., 2013a). The expression
of miR-365 is lower in melanoma cells than in normal
melanocytes, and it was observed that overexpression
of miR-365 inhibits proliferation and induces cell cycle
arrest via inhibition of its targets, CCND1 and BCL2
(Zhu et al., 2018).
A study analyzed miR-101 expression in melanoma
cell lines from stage IV melanoma patients who had
different survival times. The results suggest that sur-
vival might be favored by high levels of miR-101. In
fact, it was demonstrated that miR-101 inhibits prolif-
eration through the downregulation of MITF and
EZH2 (Luo et al., 2013a). Despite this observation,
miR-101 is not considered to be a classical tumor sup-
pressor because of its low expression in human mela-
nocytes (NHEM).
In addition to miR-211, there is a group of miR-
NAs, namely, miR-203, -204 and -205, which show
skin-specific expression. All of these miRNAs have
been found to be dysregulated in melanoma. Specifi-
cally, miR-205 is downregulated in metastatic and pri-
mary melanomas compared with benign nevi (Xu
et al., 2012). This finding was confirmed by Hanna
et al. (2012), who also demonstrated that miR-205
downregulation is associated with worse clinical out-
come. Overexpression of miR-205 in cell lines reduced
anchorage-independent colony formation, thereby
reducing survival capability (Franken et al., 2006; Liu
et al., 2012b), and is also correlated with zinc-finger
E-box binding homeobox 2 (ZEB2) downregulation,
E-cadherin upregulation (Liu et al., 2012b) and sup-
pression of cell proliferation via E2F1 and E2F5
targeting (Dar et al., 2011).
Both miR-203 and 126/126* were found to be down-
regulated in melanoma, in particular in metastatic mel-
anoma. Specifically, the downregulation of miR-203
was inversely correlated with B lymphoma Mo-MLV
insertion region 1 homolog (BMI1) levels. It was
demonstrated that miR-203 inhibits the proliferation
by targeting BMI1, thereby reducing invasion and
tumor sphere formation (Chang et al., 2015). In addi-
tion, it was observed that ectopic expression of miR-
203 in melanoma cells reduced the expression of
E2F3a and E2F3b, leading to the inhibition of cell
growth and induction of cell cycle arrest and senes-
cence (Noguchi et al., 2012b). It was experimentally
demonstrated that restored expression of miR-126/
126* reduces cell proliferation, invasion in vitro, and
melanoma growth and dissemination in vivo. The
opposite effect was observed when miR-126/126* were
silenced, probably due to their direct action on two
metalloproteases, namely ADAM9 and MMP7, which
play a pivotal role in melanoma progression (Felli
et al., 2013).
Another miRNA with a tumor suppressor role in
melanoma is miR-194. It was observed that the over-
expression of miR-194 inhibits cell proliferation
through the PI3K/AKT/FoxO3a signaling pathway
(Bai et al., 2017). In addition, another study observed
that the inhibition of proliferation by miR-194 can be
due to the negative regulation of Rho guanine nucleo-
tide exchange factor 2 (GEF-H1) (Guo et al., 2016b).
They also observed a negative association between
miR-194 expression and TNM stages.
There was significant downregulation of miR-485-5p
in melanoma tissue and cell lines compared with corre-
sponding controls. It was observed that the overex-
pression of miR-485-5p inhibits proliferation and
invasion mediated by the downregulation of Frizzled7
(FZD7), indicating a role of miR-485-5p in the regula-
tion of Wnt signaling (Wu et al., 2017).
Another miRNA linked to the Wnt pathway is miR-
136. The expression level of miR-136 is decreased in
mouse melanoma cells and is linked to the progression
of melanoma. It was observed that miR-136 acts as a
tumor suppressor by inhibiting proliferation, migration
and invasion, and promoting apoptosis. The action of
miR-136 is mediated by the inhibition of preme-
lanosome protein (PMEL), resulting in the downregula-
tion of the Wnt signaling pathway (Wang et al., 2017b).
Most of the functional studies on the role of miR-
NAs in melanoma were performed using melanoma
cell lines in vitro. There are a few recent studies that
used miRNA mimics or anti-miRNA molecules to
treat melanoma in vivo. All of them were based on the
use of melanoma-derived cells that were injected into
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immunocompromised mice. No in vivo miRNA study
has yet been performed using genetically engineered
mouse models of melanoma (Perez-Guijarro et al.,
2017) or patient-derived xenografts (PDX) (Yan et al.,
2018).
Zheng et al. (2018) found that overexpression of
SOX10 promoted melanoma cell proliferation and
chemotherapy resistance both in vitro and in vivo, and
was associated with poor overall survival. They also
demonstrated that miR-31 could regulate tumor cell
growth and chemosensitivity of melanoma cells by
suppressing SOX10. The miR-31–SOX10 axis mediates
tumor growth and drug resistance through activation
of the PI3K/AKT signaling pathway.
2.1.3. MicroRNAs involved in apoptosis
Uncontrolled cell growth involves the loss of control of
apoptosis. Certain proteins, including BCL2 and
BCL2-like 1, have anti-apoptotic roles and can be the
target of specific miRNAs. Furthermore, p53 activity is
positively and negatively regulated by specific miRNAs
(Feng et al., 2011; Liu et al., 2017). One of them is
miR-18b, which upregulates p53 by downregulating
mouse double minute 2 homolog (MDM2); miR-18b
was found to be downregulated in melanoma compared
with benign nevi and its downregulation was responsi-
ble for decreased p53 activity (Dar et al., 2013).
Overexpression of miR-638 is reported in metastatic
lesions compared with primary melanomas; it down-
regulates the TP53INP2 oncosuppressor and thereby
protects melanoma cells from apoptosis and autophagy
(Bhattacharya et al., 2015).
There are many miRNAs already known to be
involved in the control of proliferation and cell cycle
that also affect apoptosis. One of them is the oncomiR
miR-21 (Yang et al., 2011). Jiang et al. (2012) reported
upregulation of PTEN upon miR-21 inhibition, and
also observed changes in B-cell lymphoma 2 (BCL-2)
and phosphorylated RAC-alpha serine/threonine-pro-
tein kinase (pAKT). Furthermore, miR-21-5p expres-
sion can be induced by UV irradiation in human
keratinocytes (Syed et al., 2013).
Compared with benign melanocytes, melanoma exhi-
bits upregulated expression of miR-4286, which pro-
motes proliferation and protects from apoptosis. The
use of miR-4286 inhibitors leads to the alteration of
miR-4286 targets that are implicated in proliferation
and apoptosis pathways: folylpolyglutamate synthase
(FPGS), RNA polymerase I-specific transcription initi-
ation factor (RRN3), apelin (APLN), G-protein-
coupled receptor 55 (GPR 55) and high-mobility group
A1 protein (HMGA1) (Komina et al., 2016).
A significant upregulation of miR-15b is seen in
melanoma compared with melanocytic nevi. High
expression of miR-15b is correlated with worse sur-
vival. Downregulation of miR-15b inhibits cell prolif-
eration and promotes apoptosis. It was observed that
high levels of miR-15b are associated with an increase
of caspase 3 and 7, and annexin V, whereas Bcl-2 was
not induced. This suggests that miR-15b may promote
apoptosis independently of Bcl-2 in melanoma cells
(Satzger et al., 2010).
In addition to the earlier described role in cell prolif-
eration, miR-125b can also affect senescence and
apoptosis. In fact, miR-125b-transfected cells showed
increased levels of p27, p53 and p21, and consequently
induced senescence (Nyholm et al., 2014).
The miRNA miR-205 is considered a tumor sup-
pressor for promoting apoptosis: Dar et al. (2011) sug-
gested that the downregulation of miR-205 in
metastatic melanomas may lead to the activation of
E2F transcription factor 1 (E2F1) and the inhibition
of Rb.
Reuland et al. (2013) studied the role of miR-26a in
melanoma: they observed downregulation of this
miRNA in melanoma cells compared with normal mel-
anocytes. In addition, the replacement of miR-26a pro-
moted cell death by targeting directly the anti-
apoptotic protein silencer of death domains (SODD)
(Reuland et al., 2013).
2.1.4. MicroRNAs involved in invasion and metastasis
For the development of metastasis, it is necessary for
the tumor to acquire the capacity to migrate and go
through a de-differentiation program called epithelial-
mesenchymal transition (EMT).
The upregulation of miR-150, observed in primary
and metastatic melanoma in comparison with congeni-
tal nevi (Segura et al., 2010), was implicated in cellular
proliferation and cellular migration (Howard et al.,
2013; Walker et al., 1998) through the activity of miR-
150 on targets such as v-myb avian myeloblastosis viral
oncogene homolog (MYB), early growth response 2
(EGR2) and neurogenic locus notch homolog protein 3
(NOTCH3), as well as on immune system-related genes,
cytokine signaling cascades and G-proteins (Fleming
et al., 2015; Howard et al., 2013; Kunz, 2013).
It has been reported that reducing miR-211 expres-
sion using a miR-211 specific ‘antagomir’ enhanced
melanoma invasiveness 10-fold. Conversely, overex-
pression of miR-211 decreased the invasive potential
of melanoma cells, but did not change the growth rate
(Levy et al., 2010). The miR-211 caused reduced
expression of transforming growth factor beta (TGFb),
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which furthered invasion and melanoma metastasis
(Levy et al., 2010). Overexpression of miR-211 can
also result in decreased expression of brain-specific
homeobox/POU domain protein (BRN2) (Boyle et al.,
2011) and ion channel KCNMA1 (Mazar et al., 2010),
the upregulation of which is associated with increased
cellular invasion in melanoma and other cancers.
In addition to its involvement in proliferation, miR-
101 inhibits the invasion of melanoma cells, likely due
to the downregulation of its target MITF and EXH2
genes (Luo et al., 2013a).
The miR-200 family plays an important role in
cancer migration. The expression of the miR-200
family is upregulated in melanoma and promotes
tumor cell migration. In particular, the transfection
of miR-200c in melanoma cells induces an ameboid-
like invasion mode, with the cells assuming a round
cell-body phenotype. It was suggested that the effect
could be due to the downregulation of MARCKS,
which is important for the formation of cell protru-
sions. On the other hand, miR-200a promotes the
protrusion-associated elongated invasion mode
because it reduces actomyosin contractility, which is
a feature of a rounded phenotype (Elson-Schwab
et al., 2010).
In melanoma, miR-203 is downregulated and conse-
quently its target BMI1 is upregulated. It was observed
that overexpression of miR-203, in addition to sup-
pressing proliferation, leads to the inhibition of the
invasiveness in melanoma (Chang et al., 2015).
Low expression levels of miR-9 were seen in meta-
static melanoma compared with primary melanoma. In
melanoma, miR-9 acts as a tumor suppressor. Its role
consists in metastasis inhibition by the downregulation
of Zinc-finger protein SNAI1 (Snail1) and nuclear fac-
tor kappa-light-chain-enhancer of activated B cells
(NF-jB1) and by upregulation of E-cadherin (Liu
et al., 2012a).
In melanoma cell lines, miR-182 was found upregu-
lated and its overexpression promoted metastasis by
repressing FOXO3 and MITF (Segura et al., 2009).
It was demonstrated that miR-21 upregulation pro-
motes invasiveness through the downregulation of the
tissue inhibitor of metalloproteinase-3 (TIMP3) (Mar-
tin del Campo et al., 2015; Yang et al., 2011). In this
study, mice treated with anti-miR-21 molecules showed
a significant reduction of TIMP3 expression and tumor
growth and invasiveness.
It has been reported that let-7a is downregulated in
melanoma cells compared with melanocytes (Muller
and Bosserhoff, 2008). Moreover, this miRNA targets
neuroblastoma RAS viral oncogenes homolog (NRAS)
and human integrin b3, which have a well-documented
role in melanoma progression and invasion. The
amount of let-7a has been linked to upregulation of
integrin b3 in melanoma cells (as shown by transient
in vitro overexpression and luciferase assays), indicat-
ing that this miRNA has a tumor-suppressive role in
melanoma (Muller and Bosserhoff, 2008).
The miR-34a is part of the miR-34 family (miR-34a/
b/c) that is regulated by p53. In human melanoma cell
lines, the overexpression of the miR-34 family inhibits
the growth and invasion of cells expressing wild-type
p53 gene (Yamazaki et al., 2012). There is significant
downregulation of miR-34a in metastatic melanoma
compared with in situ melanoma, nevi and normal
melanocytes. The high expression of miR-34a also
inhibits proliferation and metastasis by targeting flotil-
lin 2 (FLOT2) (Liu et al., 2015b).
A strong downregulation of miR-365 was shown in
malignant melanoma tissue and cells lines. The ectopic
expression of miR-365 inhibits growth, invasion and
metastasis in malignant melanoma by directly targeting
neuropilin-1 (NPL1) (Bai et al., 2015).
Giles et al. (2013) studied the role of miR-7-5p in
melanoma. They observed a downregulation of miR-7-
5p in metastatic melanoma-derived cell lines compared
with primary melanoma cells. Furthermore, the ectopic
expression of miR-7-5p suppresses cell migration and
invasion by directly targeting insulin receptor sub-
strate-2 (IRS-2), and the inhibition of IRS-2 reduced
the activity of protein kinase B (AKT) (Giles et al.,
2013).
MicroRNA miR-125b is downregulated in mela-
noma especially in metastatic melanoma; miR-125b
acts as tumor suppressor and decreases cell migration
(Kappelmann et al., 2013). This could be mediated by
the downregulation of the transcription factor c-Jun
(Kappelmann et al., 2013) and serine/threonine kinase
mixed lineage kinase (MLK3) protein and mitogen-
activated protein kinase kinase 7 (MMK7), which are
direct targets of miR-125b (Zhang et al., 2014).
Melanoma cell lines and tissues showed a downregu-
lation of miR-542-3p. It was observed that the ectopic
expression of miR-542-3p suppresses tumor cell migra-
tion, invasion and EMT through the inhibition of its
target, the proto-oncogene serine/threonine protein
kinase (PIM1) (Rang et al., 2016). The expression
levels of miR-124 were negatively correlated with the
advanced stage of melanoma. The tumor suppressor
effect of miRNA-124 consisted in the suppression of
proliferation and invasion mediated by the inhibition
of its target RLIP76, which is overexpressed in mela-
noma cell lines (Zhang et al., 2016). MicroR-625 was
found downregulated in malignant melanoma and it
was shown that its ectopic expression inhibits
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proliferation and migration in malignant melanoma.
In particular, in malignant melanoma, the expression
level of miR-625 was inversely correlated with that of
transcription factor SOX-2 (SOX2), suggesting that
the anti-tumor action of miR-625 is at least partially
mediated by the inhibition of SOX2 (Fang et al.,
2017).
Also, miR-153-3p is downregulated in melanoma tis-
sue and cell lines. In particular, it was observed that
miR-153-3p modulates cell proliferation and invasion
by the inhibition of the expression of SNAI1, which is
a zinc-finger transcription factor involved in the pro-
motion of the EMT (Zeng et al., 2017).
MicroRNA miR-137 acts as tumor suppressor; in
fact, the expression of miR-137 in melanoma leads to
the inhibition of the proliferation and invasion by the
downregulation of its targets, including MITF, c-Met,
Y-box-binding protein 1 (YB-1) and enhancer of zeste
homolog 2 (EZH2). In addition, a correlation was
observed between miR-137 expression and prognosis;
low levels of miR-137 are associated with a short sur-
vival in stage IV melanoma patients (Luo et al., 2013b).
Weber et al. (2016) performed a very interesting
study where they tested a large panel of miRNA mim-
ics to assess their effect on melanoma A375 cell line
invasion capability. They identified the miRNAs that
were most effective in promoting cell invasion (miR-
576-5p, miR-21, miR-214 and miR-182) and those that
were most effective in preventing cell invasion (miR-
339-3p, miR-211, miR-101, miR-126-3p and -5p). They
then tested the effect of miR-339-3p in vivo by per-
forming lung colonization assays in immunodeficient
NSG mice. They found that mice injected with A375
cells overexpressing miR-339-3p carried significantly
fewer tumor nodules compared with control mice, con-
sistent with the inhibitory effect of miR-339-3p on
tumor cell invasion in vitro. In addition, they blocked
miR-339-3p using an antagomir and found an increase
of melanoma cell invasion, an effect that could be phe-
nocopied by RNAi-mediated silencing of MCL1,
which is a target of miR-339-3p.
Orso et al. (2016) studied the role of miR-214 and
miR-148b in the process of metastatic dissemination.
Depleting miR-214 or elevating miR-148b blocked the
dissemination of melanoma, an effect that could be
accentuated by their dual alteration (Orso et al., 2016).
In fact, they demonstrated that the dual alteration sup-
presses the passage of malignant cells through the
blood vessel endothelium by reducing the expression
of the cell adhesion molecules ITGA5 and ALCAM;
furthermore, single or combined miR-214 downregula-
tion and miR-148b upregulation in tumor cells inhibits
metastasis formation in mice.
2.1.5. MicroRNA involved in immune response
One hallmark of melanoma biology is immune eva-
sion. This can be induced by senescence, alterations in
antigen presentation, interference with regulatory T
cells or hypoxia (Noman et al., 2012). The role of the
immune system in melanoma is widely known and
immunotherapies based on immune checkpoint
(CTLA4 and PD1) inhibitors have been developed,
such as anti-CTLA4 and anti-PD1 (Postow et al.,
2015). Recently, some evidence of the immune sup-
pressive/evasive effects of families of miRNAs.
Immune escape can be promoted by a hypoxic
microenvironment (Noman et al., 2011). In melanoma,
hypoxia-induced miR-210 expression level resulted in
the escape from cell lysis by antigen-specific cytotoxic
T lymphocytes (CTL or CD8+ T cells) (Noman et al.,
2012). In the same study, it was observed that in
hypoxic cells, miR-210 targets and inhibits protein tyr-
osine phosphatase non-receptor type 1 (PTPN1),
homeobox protein Hox-A1 (HOXA1) and tumor pro-
tein p53-inducible protein 11 (TP53I11; Noman et al.,
2012).
MicroRNA-30b and -30d act as immunosuppressive
miRNAs. It was observed that miR-30b and miR-30d
are upregulated in melanoma, and their increased
expression level correlates with an advanced stage,
metastatic potential and a worse prognosis. The ecto-
pic expression of miR-30b/30d leads to the downregu-
lation of GalNAc transferase GALNT7, resulting in
suppression of immune cell activation and recruitment
mediated by a high level of immunosuppressive cyto-
kine IL-10 (Gaziel-Sovran et al., 2011).
Other miRNAs that are able to influence the
immune response are miR-34a/c. In particular, miR-
34a/c control the expression of UL16 binding protein
2 (ULBP2), which is a ligand for NK cell immunore-
ceptor NKG2D. The downregulation of miR-34a/c,
which occurs frequently in cancer, leads to an upregu-
lation of ULBP2, thus paradoxically resulting in an
increased tumor-immune surveillance by natural killer
(NK) cells (Heinemann et al., 2012).
The microRNAs miR-21, miR-29a, miR-142-3p and
miR-223 are induced in macrophages by activation of
CSF1-ETS2 pathway and can influence melanoma
growth and metastasis. Consistently, miR-21 and miR-
29a are upregulated in specific suppressive myeloid
populations in mouse bone marrow and patient blood
during melanoma metastatic progression (Mathsyaraja
et al., 2015). MicroRNAs miR-34a/c and miR-499a/c
bind to the 30-UTR of ULBP2, a ligand of NKG2D
receptor that activates NK cells against the tumor
(Heinemann et al., 2012).
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Ultraviolet radiation is the main risk factor for CM.
Experimental models for UV-induced melanoma have
highlighted that UVR-induced inflammation can pro-
mote immune evasion (Hodis et al., 2012). Recently,
the effect of UV exposure on miRNA expression in
melanocytic nevi was explored (Bell et al., 2018) and a
depth-related signature was identified. Another recent
study demonstrated that 14 miRNAs are altered after
UV exposure, leading to the increase of immune eva-
sive molecules such as CCL2, CCL8, PD1 and B7H2
(Sha et al., 2016).
MicroRNAs can also be involved in immune check-
point regulation; in fact, exhausted T cells in mela-
noma show a downregulation of miR-28 expression.
MicroRNA miR-28 binds the 30-UTR of TIM3, BTLA
and PD-1. When miR-28 mimics were administered to
exhausted T cells, the phenotype reverted and IL-2
and tumor necrosis factor (TNF)-a production
restored (Li et al., 2016). Because of PD-L1 regulation,
miR-17-5p has also been proposed as a prognostic bio-
marker. BRAF- and MEK-inhibitor-resistant mela-
noma cell lines showed increased expression of PD-L1,
which is inversely correlated with miR-17-5p expres-
sion. The authors demonstrated that PD-L1 is a direct
post-transcriptional target of miR-17-5p (Audrito
et al., 2017).
2.2. MicroRNAs as diagnostic or prognostic
biomarkers
2.2.1. Circulating miRNAs in melanoma
An important characteristic of miRNAs is that they
are released by the tumor in the bloodstream. Tumor-
derived endogenous miRNAs are very stable in the
blood and are resistant to RNAse activity. It is possi-
ble to analysis miRNA levels in blood samples in a
non-invasive way, performing a ‘liquid biopsy’. In
2008, it was reported for the first time that circulating
miRNAs could be used as biomarkers in patients with
solid tumors (Mitchell et al., 2008). Circulating miR-
NAs can be used for cancer diagnosis and prognosis
(Ferracin and Negrini, 2015). The circulating miRNA
profile is different from that of tumors and relies
strongly on the protocol used for sample processing,
probably because of the different amount of extracellu-
lar vesicles (EVs) retained during plasma/serum prepa-
ration. Indeed, exosomes and EVs in general are one
of the main repositories of miRNAs in the blood
(Cheng et al., 2014).
Some pilot studies for the analysis of the entire spec-
trum of circulating miRNAs by microarray and small
RNA sequencing (Ferracin et al., 2015) or quantitative
PCR (Greenberg et al., 2013; Stark et al., 2015b) have
been performed in the past few years. Ferracin et al.
(2015) demonstrated the potential of miR-320a as a
plasma melanoma biomarker in comparison with other
main types of solid tumors and healthy subjects. In
contrast, in their study, Greenberg et al. (2013)
showed that there was a significant reduction of circu-
lating miR-29c and miR-324-3p in the serum of mela-
noma patients compared with healthy subjects. The
decrease of miR-29c expression was also observed in
stage III/IV compared with stage I/II melanoma
tumors and it was associated with a poor prognosis in
CM (Nguyen et al., 2011). Stark et al. (2015b) per-
formed a screening on the level of 233 miRNAs in
melanoma and healthy controls and across melanoma
stages. They identified a panel of 17 miRNAs (MEL-
miR-17 signature) that was correlated with stage,
recurrence and survival and with a predictive potential.
In that study, they further selected a panel of seven
miRNAs that was able to detect the presence of mela-
noma with high sensitivity (93%) and specificity
(82%). In this panel, miR-4487, miR-4706, miR-4731,
miR-509-3p and miR-509-5p were reduced, whereas
miR-16 and miR-211 (stage IV only) were increased in
melanoma.
Another panel was proposed by Margue et al.
(2015), who found that in serum samples of melanoma
patients the levels of miR-122-5p and miR-3201 were
higher than in serum samples of healthy people.
In another study, the quantification of 21 miRNAs
in the plasma of melanoma patients and healthy sub-
jects identified five miRNAs that can be used as diag-
nostic markers. In particular, the upregulation of
circulating miR-149-3p, miR-150-5p and miR-15b-5p,
and the downregulation of circulating miR-193a-3p
and miR-524-5p were associated to melanoma (Fogli
et al., 2017).
Armand-Labit et al. (2016) demonstrated that the
detection of miR-185 and miR-1246 in plasma discrim-
inated patients with metastatic melanoma from healthy
individuals with a sensitivity of 90.5% and specificity
of 89.1%.
Circulating miRNA can also be used to provide
prognostic information. Friedman et al. (2012) pro-
posed a panel of five circulating miRNAs to identify
melanoma patients with high risk of recurrence. In
particular, they found that in melanoma patients’
serum samples, low levels of miR-15b and miR-33a,
and elevated levels of miR-150, miR-199a-5p and miR-
424 were associated with a high risk of recurrence.
A predictive panel formed by miR-150-5p, miR-30d-
5p, miR-15b-5p and miR-425-5p in conjunction with
the pathologic stage was superior for predicting
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recurrence-free and overall survival when compared
with conventional staging criteria. In addition, it was
shown that miR-15b levels can be useful for early
monitoring for recurrence in melanoma patients
(Fleming et al., 2015).
Shiiyama et al. (2013) proposed a panel of six miR-
NAs to identify metastatic melanoma. In fact, the
expression of miR-150-5p, miR-9-5p, miR-145-5p,
miR-155-5p, miR-203 and miR-205-5p was signifi-
cantly different in metastatic and non-metastatic mela-
noma patients.
In a case–control study, it was found that the
expression of circulating miR-16 can be used as a
prognostic biomarker. Expression levels of miR-16
were lower in serum of melanoma patients than in
serum of cancer-free controls. Furthermore, it was
shown that the decrease of miR-16 was correlated with
an increase in tumor thickness, ulceration status,
AJCC stage, and tissue Ki-67 expression (Guo et al.,
2016a).
 A comparison of miR-206 levels between 60
patients with melanoma and 30 healthy controls
showed that serum levels of miR-206 are signifi-
cantly lower in melanoma. In addition, a correla-
tion between miR-206 levels and prognosis was
reported. In fact, it was observed that patients
with low serum miR-206 levels present two or
more sites of metastases and had a shorter 5-
year overall and disease-free survival than mela-
noma patients with a high miR-206 level (Tian
et al., 2015).
 Plasma levels of miR-21 were found to be ele-
vated in melanoma in two independent studies
(Ferracin et al., 2015; Saldanha et al., 2013).
Plasma levels of miR-210 were higher in individ-
uals with melanoma and an increased level of
miR-210 predicted disease recurrence. Further-
more, miR-210 increase in plasma was correlated
with a poor prognosis (Ono et al., 2015).
MicroRNA miR-221-5p was shown to be increased
in the serum of patients with metastatic melanoma,
decreasing after excision and increasing with disease
recurrence (Kanemaru et al., 2011).
The level of miR-125b-5p in serum-derived exo-
somes of 21 patients with advanced melanoma was
compared with that in 16 disease-free patients and 19
healthy volunteers; miR-125b-5p expression was
reduced in exosomes of individuals with an active dis-
ease (Alegre et al., 2014).
Xiao et al. (2016) demonstrated that melanoma cell-
derived exosomes actively interact with normal mela-
nocytes. They also suggest that melanoma cell-derived
exosomes may promote the EMT-resembling process
through autocrine/paracrine signaling, creating a
tumor-supportive microenvironment, through the
action of miR-191 and let-7a.
Pfeffer et al. (2015) investigated miRNA signatures
of plasma-derived exosomes from familial and spo-
radic melanoma patients and unaffected family mem-
bers. They demonstrated that miR-17, miR-19a, miR-
21, miR-126 and miR-149 are expressed at higher
levels in plasma-derived exosomes from patients with
metastatic melanoma. They then studied plasma from
genetically predisposed familial melanoma patients
with/without evidence of disease. They did not found
differences between CDKN2A mutation carriers and
controls.
Lunavat et al. found that inhibition of BRAFV600E
with vemurafenib and dabrafenib was associated with
increased secretion of EVs from melanoma cells. They
observed the specific increase of miR-211-5p after
treatment in cells and EVs both in vitro and in vivo.
This result indicated that target therapies change the
RNA cargo in tumor-derived EVs. In addition, miR-
211-5p forced expression reduced sensitivity to BRAF
inhibitors and decreased its efficiency in melanoma cell
lines (Lunavat et al., 2017).
MicroRNA miR-222 is involved in melanoma devel-
opment by controlling tumor progression through the
down-modulation of its target genes: p27Kip1/
CDKN1B, c-KIT and c-FOS (Felicetti et al., 2008). It
was later discovered that miR-222 can be detected in
exosomes from human melanoma cell lines established
from primary or metastatic tumors. It has been also
demonstrated that miR-222 can be transferred between
cells, resulting in the capability of promoting malig-
nancy through p27Kip1 inhibition and consequent
PI3K/AKT pathway activation in the recipient cells
(Felicetti et al., 2016).
A summary of the miRNAs that can be detected in
the circulation in melanoma is presented in Table 2.
2.2.2. MicroRNAs in prognosis prediction and drug
resistance
The dysregulated expression of specific miRNAs in
melanoma cells could serve as a prognostic biomarker
for the patients or interfere with their response to treat-
ments (Table 3). Expression of miR-21-5p is an impor-
tant prognostic factor in melanoma, where its increased
expression was correlated with higher tumor stage and
worst survival (Jiang et al., 2012). Galasso et al. (2018)
demonstrated that the loss of miR-204 is common in
melanomas with NRAS sole mutation but is less fre-
quent in those harboring CDKN2A mutations.
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Additionally, miR-204 was associated with a better
prognosis in two independent melanoma cohorts and
its exogenous expression led to growth impairment in
melanoma cell lines (Galasso et al., 2018).
Segura et al. established a signature of 18 miRNAs
associated with metastatic melanoma survival. In par-
ticular, they showed that metastatic patients had a
longer survival when the metastasis was overexpressing
Table 2. Circulating miRNAs with a diagnostic, prognostic or functional impact in melanoma.
miRNA Significance
Levels in melanoma patients vs.
healthy subjects References
320a Diagnostic marker Increased Ferracin et al. (2015)
29c, 324-3p Diagnostic marker Decreased Greenberg et al. (2013)
4487, 4706, 4731, 509-3p,
509-5p
Diagnostic marker Decreased Stark et al. (2015b)
16-5p, 211-5p Increased (only stage IV)
29c-3p Staging (III/IV vs. I/II) Decreased Nguyen et al. (2011)
122-5p, 3201 Diagnostic marker Increased Margue et al. (2015)
149-3p, 150-5p, 15b-5p Diagnostic marker Increased Fogli et al. (2017)
193a-3p, 524-5p Decreased
185-5p, 1246 Diagnostic marker Increased Armand-Labit et al. (2016)
15b-5p, 33a-5p Prognostic marker Decreased Friedman et al. (2012)
150-5p, 199a-5p, 424-5p Increased
150-5p, 30d-5p, 15b-5p, 425-5p Prognostic marker Fleming et al. (2015)
150-5p, 9-5p, 145-5p, 155-5p,
203, 205-5p
Metastasis marker Shiiyama et al. (2013)
16-5p Prognostic marker Decreased Guo et al. (2016a)
206 Diagnostic and
prognostic marker
Decreased Tian et al. (2015)
21-5p Diagnostic and
prognostic marker
Increased Ferracin et al. (2015), Saldanha et al.
(2013)
210 Diagnostic and
prognostic marker
Increased Ono et al. (2015)
221-5p Prognostic marker Increased Igoucheva and Alexeev (2009),
Kanemaru et al. (2011)
125b-5p Diagnostic marker Decreased Alegre et al. (2014)
191 and let-7a EMT Released in exosomes Xiao et al. (2016)
17-5p, 19a-3p, 21-5p, 126-3p,
149-5p
Diagnostic marker Released in exosomes Pfeffer et al. (2015)
211–5p Therapy resistance Released in exosomes Lunavat et al. (2017)
222-3p Malignant
transformation
Released in exosomes Felicetti et al. (2016)
Table 3. MicroRNAs (miRNAs) involved in prognosis prediction and drug resistance.
miRNA Significance Expression Reference
21-5p Prognostic marker Upregulated in the worse prognosis group Jiang et al. (2012)
204-5p Prognostic marker Downregulated in NRASmut Galasso et al. (2018)
150-5p, 455-3p, 145-5p,
342-3p, 497-5p, 155,
342-5p, 143-3p, 193a-3p,
146b-5p, 28-3p, 10b-5p,
193b-3p, 28-5p, 142-5p,
143-5p, 126-3p, 214-3p
Prognostic marker Upregulated in the better prognosis group Segura et al. (2010)
34a-5p, 100-5p, 125b-5p Resistance to BRAF inhibitors Upregulated in resistant cells Vergani et al. (2016)
514a-3p Resistance to BRAF inhibitors Upregulated in resistant cells Stark et al. (2015a)
200c-3p Sensitivity to BRAF inhibitors Upregulated in resistant cells Liu et al. (2015a)
579-3p Resistance to BRAF/MEK inhibitors Downregulated in resistant cells Fattore et al. (2016)
87Molecular Oncology 13 (2019) 74–98 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
M. Riefolo et al. Non-coding RNAs in melanoma onset and progression
these miRNAs (miR-150, mir-455-3p, miR-145, miR-
342-3p, miR-497, miR-155, miR-342-5p, miR-143,
miR-193a-3p, miR-146b-5p, miR-28-3p, miR-10b,
miR-193b, miR-28-5p, miR-142-5p, miR-143*, miR-
126 and miR-214) (Segura et al., 2010). In addition,
they proposed a reduced 6-miRNA panel (miR-150,
miR-455-3p, miR-145, miR-497, miR-155, miR-342-
3p) to stratify stage III patients according to prognosis
and also demonstrated its validity in primary tumors.
Several miRNAs can affect drug resistance in mela-
noma. It was observed that melanoma could acquire
resistance against BRAF inhibitors by altering the pat-
tern of cytokine production. The treatment with
BRAF inhibitor vemurafenib led to an increase of
CCL2, which acts as an autocrine growth factor in
melanoma. CCL2 in turn upregulates miR-34a, miR-
100 and miR-125b (Vergani et al., 2016). In that
study, high levels of these miRNAs were associated
with apoptosis inhibition and drug resistance. The
simultaneous inhibition of all the three miRNAs
restored sensitivity to BRAF inhibitors by increasing
apoptosis.
Another study observed that in melanoma, miR-514
contributed to the sensitivity of BRAF inhibitors.
Specifically, miR-514 targets NF1 and leads to the
maintenance of MAPK pathway activation. In this
way, the overexpression of miR-514 contributes to the
resistance to BRAF inhibitors (Stark et al., 2015a).
Liu et al. (2015a) investigated the role of miR-200c
in resistance of BRAF inhibitors. They observed a
downregulation of miR-200c in resistant melanoma
tumors and cell lines, with a consequent upregulation
of its targets, including BMI1, ZEB2, TUBB3, ABCG5
and MDR1. The study showed that the overexpression
of miR-200c restores the sensitivity of BRAF inhibi-
tors through the inhibition of PI3K/AKT and MAPK
signaling pathways.
Fattore et al. (2016) found that the expression of
miR-579-3p is a prognostic factor; in particular, low
levels of miR-579-3p are associated with a poor prog-
nosis. They observed that the expression levels
decrease from nevi to stage III/IV melanoma samples
and also that melanoma cell lines resistant to BRAF/
MEK inhibitors showed a downregulation of this
miRNA. The overexpression of miR-579-3p altered the
drug sensitivity in melanoma cell lines.
2.3. MicroRNA editing in melanoma
RNA editing is the post-translational process that
changes the sequence of a transcribed RNA. This
event is mediated by specific enzymes, including mem-
bers of double-stranded RNA-specific adenosine
deaminase (ADAR) and activation-induced cytidine
deaminase or its relative APOBEC cytidine deaminase
families, which can be dysregulated in cancer (Por-
cellini et al., 2018). Specifically, mature miRNA
nucleotides can be subjected to hydrolytic deamination
of adenosine to inosine (A-to-I) or C-to-U conversion.
In melanoma, a downregulation of ADAR1 in meta-
static tumors was reported and correlated with reduced
A-to-I editing of miR-455-5p, miR-324-5p and miR-
378a-3p (Shoshan et al., 2015). The changes in miR-
455-5p editing sites modified its activity on the target
genes and conferred completely different biological
functions on this miRNA.
Velazquez-Torres et al. (2018) studied the effect of
ADAR1 hypo-editing in metastatic melanoma cells.
Micro (mi)R-378a-3p undergoes A-to-I modification
only in the non-metastatic melanoma cells. The target
of miR-378a-3p is the oncogene PARVA, but the gene
is preferentially downregulated by the edited form of
miR-378a-3p. In melanoma cells, the expression of a-
parvin and ADAR1 is inversely correlated. When they
transfected the WT and edited form of miR-378a-3p in
SB2 cells, a-parvin expression reduction was observed
only upon edited miR-378a-3p transfection.
Nemlich et al. (2013) studied metastatic melanoma
cells that exhibit significant downregulation of
ADAR1-P110 and ADAR1-P150 as compared with
normal melanocytes, nevi and primary melanoma
tumors. They reported that miR-17-5p and miR-432
are direct, independent, endogenous cellular regulators
of ADAR1. They also observed that the upregulation
of miR-21-5p (by silencing) and the downregulation of
miR-34a (by forced expression) seems partially to
reverse the enhanced proliferation of ADAR1-KD
cells. They also showed that amplification of the geno-
mic segment encoding miR-17-5p occurs frequently in
melanoma, facilitating the malignant phenotype by
directly targeting ADAR1. In addition, the overexpres-
sion of miR-432 in melanoma can be attributed to fre-
quent genomic amplification and aberrant
hypomethylation patterns of the DLK1-DIO3 locus on
chromosome 14.
2.4. Long non-coding RNA dysregulation in
melanoma
Besides small ncRNAs, several recent studies described
the dysregulation and cancer-promoting role of specific
lncRNAs in CM (Table 4). From these studies, some
lncRNAs were associated with stage (Yang et al.,
2018) or metastasis (Wang et al., 2017a). Recently,
two prognostic lncRNA signatures were proposed
(Chen et al., 2017b; Yang et al., 2018), demonstrating
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the potential of lncRNA in melanoma classification.
Functionally, the mechanisms used by two melanoma-
specific lncRNAs (SAMMSON and TYRP1) to pro-
mote tumor growth were recently described (Gilot
et al., 2017; Leucci et al., 2016). The lncRNA SAMM-
SON is located in a genomic region that is amplified
in melanoma and interacts with the mitochondrial pro-
tein p32 in regulating the survival of melanoma cells
(Leucci et al., 2016). TYRP1 mRNA, independently of
its protein-coding activity, sequestering through its 30-
UTR a microRNA (miR-16) and thus dampening the
tumor suppressor activity of miR-16 itself (Gilot et al.,
2017).
Sprouty4-intronic transcript 1 (SPRY4-IT1) is one
of the first described lncRNAs associated with mela-
noma; it has been reported to promote melanoma cell
growth and invasion and inhibit apoptosis by altering
lipid metabolism (Khaitan et al., 2011; Mazar et al.,
2014). Normally, this lncRNA is expressed at low
levels in human melanocytes but it is highly upregu-
lated in human melanoma cells (Khaitan et al., 2011).
Expression levels of this lncRNA have been evaluated
in plasma of melanoma patients and matched controls,
showing that patients have higher levels of SPRY4-IT1
compared with healthy controls, associated with tumor
site, tumor stage and poor prognosis (Liu et al., 2016).
Other lncRNAs involved in melanoma cell prolifera-
tion are LLME23, UCA1 and MALAT1 (Wei et al.,
2016; Wu et al., 2013). Upregulation of LLME23 was
detected in human melanoma cell lines and it was
found to bind the protein-associated splicing factor
PSF, a well-known tumor suppressor; by binding to
PSF, LLME23 was able to promote the expression of
the proto-oncogene RAB23, a RAS-related small
GTPase (Wu et al., 2013). Moreover, LLME23 silenc-
ing reduced tumor growth in vivo.
UCA1 is upregulated in human melanoma tissues
and cell lines and is involved in tumor cell prolifera-
tion, migration and invasion. Moreover, this lncRNA
significantly increases with stages (Tian et al., 2014).
UCA1 has a binding site for miR-507, suggesting a co-
regulation of these two ncRNAs. A study on primary
melanoma, metastatic melanoma and nevi from
patients and melanoma cell lines showed that the
UCA1 level is increased in primary and metastatic
melanoma, as well as in cell lines, compared with nevi
(Wei et al., 2016). The same authors also demon-
strated a negative correlation between UCA1 and
miR-507, and that UCA1 silencing decreases the levels
of FOXM1 by releasing miR-507.
MALAT-1 was demonstrated to increase progres-
sively in melanoma progression in a cohort of 63 pri-
mary melanomas, adjacent normal tissue and
metastatic lesions (Tian et al., 2014). MALAT-1 pro-
motes cell proliferation and invasion through a com-
plex interaction with miR-183 and integrin b1
(ITGB1) (Sun et al., 2017).
In an RNA sequencing study by Flockhart et al.
(2012) the authors described a panel of 39 lncRNAs
regulated by BRAFV600E in melanoma; the most sig-
nificant was BRAF-activated non-coding RNA
(BANCR). BANCR regulates a set of genes involved
in cell migration, including the chemokine CXCL11,
and can promote melanoma proliferation via activa-
tion of ERK1/2 and JNK MAPK pathway both
in vitro and in vivo (Li et al., 2014b).
ANRIL (antisense non-coding RNA in the INK4A
locus) is a lncRNA first identified in familiar mela-
noma with CDKN2A/B (INK4B-ARF-INK4A) germ-
line mutations (Sarkar et al., 2017). ANRIL is located
in chromosome 9p21, nearby CDKN2A/B genes, and
SNPs in this region have been associated with human
Table 4. Long non-coding RNAs (lncRNAs) dysregulated in human cutaneous melanoma.
lncRNA Functional role Expression in melanoma References
SAMMSON Interacts with p32 Upregulated Leucci et al. (2016)
TYRP1 Sponge for miR-16 Upregulated Gilot et al. (2017)
SPRY4-IT1 Melanoma cell growth and invasion Upregulated Khaitan et al. (2011), Mazar et al. (2014)
SPRY4-IT1 Diagnostic and prognostic marker in serum Upregulated Liu et al. (2016)
LLME23 PSF binding Upregulated Wu et al. (2013)
UCA1 Prognostic marker Upregulated Tian et al. (2014), Wei et al. (2016)
Target of miR-507 Upregulated Wei et al. (2016)
MALAT-1 Target miR-183 and ITGB1 Upregulated Sun et al. (2017)
Prognostic marker Upregulated Tian et al. (2014)
39 lncRNAs panel Target BRAFV600E Flockhart et al. (2012)
BANCR Cell Migration Upregulated Li et al. (2014b)
ANRIL CDKN2A/B germlines deletion Upregulated Sarkar et al. (2017)
PVT1 Cell proliferation and metastasization Upregulated Chen et al. (2017a, 2018)
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diseases, e.g. coronary disease, stroke, diabetes, mela-
noma and glioma (Congrains et al., 2013). ANRIL
presents different linear and circular isoforms due to
alternative splicing, with different functional roles in
melanoma (Sarkar et al., 2017). The main function of
this lncRNA is to mediate the repression of the
CDKN2A/B locus by association with polycomb
repressor complexes (PRC1 and PRC2) involved in the
methylation-mediated control of histone3 (Richtig
et al., 2017; Yap et al., 2010). ANRIL silencing was
able to restore the proper expression of CDKN2A and
B in a melanoma xenograft model (Xu et al., 2016).
The role of plasmacytoma variant translocation 1
(PVT1) as a regulator of cell proliferation and metas-
tasis has been studied in melanoma (Chen et al.,
2017a, 2018). PVT1 is overexpressed in melanoma
samples and correlates with tumor stage. This associa-
tion was also confirmed in plasma samples, underlin-
ing the possibility of using this lncRNA as a detection
biomarker (Chen et al., 2017a). In addition, the
authors suggest a role of PVT1 in the regulation of
miR-200c expression.
Long ncRNAs could be used as targets for melanoma
treatment. Leucci et al. (2016) demonstrated that the
intravenous administration of SAMMSON-specific
antisense oligonucleotide in vivo in combination with
BRAF inhibitor dabrafenib in a melanoma patient-
derived xenograft (PDX) significantly induced apopto-
sis, reducing the tumor growth, whereas the administra-
tion of dabrafenib alone only inhibited tumor growth.
3. Concluding remarks and future
perspectives
Cutaneous melanoma typically arises on sun-exposed
skin because of the progressive accumulation of UV
radiation-induced genetic alterations. These chronically
sun-damaged (CSD) melanomas are very different
from non-CSD melanomas (Shain and Bastian, 2016).
UV exposure induces specific genetic alterations in
melanocytes (e.g. prevalence of C-to-T transition) and
a generally high tumor mutational burden, both in
coding and non-coding regions of the genome (Hay-
ward et al., 2017). This in turn generates a broad
range of genetic alterations in oncogenic drivers, as
detailed at the beginning of this review.
This heterogeneity is also reflected in the pattern of
gene expression alterations documented for this tumor.
From our analysis of the literature on ncRNAs, it is
evident that many different small and long non-coding
genes contribute to the onset and progression of mela-
noma. These ncRNA alterations are reported as recur-
rent in several studies and in large cohorts, but the
majority are is study-dependent or not yet validated in
large groups of patients. In addition, most of the pub-
lished studies mixed primary and metastatic tumors, or
did not discriminate between melanoma subtypes. For
example, no analysis of the ncRNA profile of CSD
and non-CSD melanomas has been performed yet. We
believe that this issue should be investigated in more
detail in future studies.
As far as ncRNA research in melanoma is concerned,
it is difficult to imagine that targeting a single miRNA
or lncRNA could be an effective treatment for all mela-
noma patients. There is still much work to do in this
field, especially in vivo studies for the validation of the
most interesting miRNAs, lncRNAs or combination of
these. Some interesting miRNA/lncRNA pairs which
can boost tumor growth and dissemination, were identi-
fied. Despite this potential, the relationship and mutual
interference between coding and non-coding RNAs is
still hardly studied because the quantification of all
ncRNA types in the same sample is not usually available
and computational analysis is complex.
We believe that this specific aspect of melanoma
biology deserves further investigation and a proper
integration with clinical and genomics data, in order
to find all the missing pieces in the complex jigsaw
puzzle of CM.
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